Outpatient infusion statistics at a glance
Outpatient infusion sits at the intersection of care access, site-of-service strategy, and specialty drug administration. The numbers below show a market that is large enough to support national scale, but still concentrated enough that supplier mix and drug mix matter.
This article focuses on the most recent statistics available in the supplied dataset and keeps each fact tied to its cited source label.
Quick takeaways
- Medicare home infusion therapy service visits averaged about 7,500 per quarter from Q1 2021 to Q2 2023, which suggests a fairly steady baseline rather than a one-quarter spike (CMS HIT Monitoring Report March 2024).
- Seven of 82 home infusion therapy suppliers provided about 56% of service visits in the prior 12 months, which is a strong concentration signal for the supplier side of the market (CMS HIT Monitoring Report March 2024).
- Option Care Health reported 2024 net revenue of $4.998 billion and said it would enter 2025 with more than 8,000 team members and more than 5,000 clinicians, showing the scale of a leading operator in the category (Option Care Health FY2024 earnings release).
- Home IVIG activity expanded through Q2 2025, with visits rising from 5,007 in Q1 2023 to 8,792 in Q2 2025, a useful indicator of growing outpatient infusion volume in a specialty segment (CMS Home IVIG Monitoring Report March 2026).
- InfuSystem reported 2025 net revenues of $143.4 million and nearly 840 third-party payer networks as of December 31, 2025, underscoring the breadth of payer connectivity needed in outpatient infusion-adjacent services (InfuSystem FY2025 earnings release; InfuSystem 2025 10-K).
Table of contents
- How to read these outpatient infusion statistics
- Medicare home infusion therapy volume
- Supplier concentration and service mix
- Drug mix by category
- Home IVIG growth and patient profile
- Company scale signals in outpatient infusion
- What these numbers imply for planning
How to read these outpatient infusion statistics
The phrase outpatient infusion can mean several overlapping things: Medicare-covered home infusion therapy, home IVIG delivery and administration, and large commercial outpatient infusion operations. The supplied statistics span those layers, so the most practical way to read them is to separate volume, concentration, and operator scale.
Volume tells you how much care is moving through outpatient pathways. Concentration tells you how unevenly that volume is distributed among suppliers and drugs. Scale tells you which organizations have the staffing, pharmacy, and logistics footprint to serve the market at meaningful size.
A useful way to frame the dataset is to treat the Medicare reports as demand-side evidence and the company filings as supply-side evidence. Together, they give a fuller picture than either source alone (CMS HIT Monitoring Report March 2024; CMS Home IVIG Monitoring Report March 2026; Option Care Health 2023 Annual Report; Option Care Health FY2024 earnings release; InfuSystem FY2025 earnings release; InfuSystem 2025 10-K; ICU Medical 2024 Annual Report).
Medicare home infusion therapy volume
Medicare home infusion therapy service visits averaged about 7,500 per quarter from Q1 2021 to Q2 2023 (CMS HIT Monitoring Report March 2024). That average matters because it shows a baseline market that is not purely seasonal or purely episodic. It is a working level of demand sustained across multiple quarters.
The directional trend inside that same period is also important. Service visits rose in 2021, fell slightly in 2022, and kept declining in the first half of 2023 (CMS HIT Monitoring Report March 2024). That is not the pattern of a collapsing market. It looks more like a market that expanded, normalized, and then softened at the margin.
At a glance
| Metric | Value | Source |
|---|---|---|
| Average Medicare home infusion therapy service visits | about 7,500 per quarter | CMS HIT Monitoring Report March 2024 |
| Period covered by that average | Q1 2021 to Q2 2023 | CMS HIT Monitoring Report March 2024 |
| Supplier organizations | 42 in Q1 2021 | CMS HIT Monitoring Report March 2024 |
| Supplier organizations | 74 in Q3 2022 | CMS HIT Monitoring Report March 2024 |
| Supplier organizations | 60 in Q2 2023 | CMS HIT Monitoring Report March 2024 |
That table shows an expansion in participating suppliers followed by a pullback. Supplier count grew from 42 in Q1 2021 to 74 in Q3 2022, then fell to 60 in Q2 2023 (CMS HIT Monitoring Report March 2024). The market was not static even while visits were averaging around 7,500 per quarter.
One implication is that market participation may be more volatile than aggregate visit counts. More suppliers entered, but not all of them stayed active at peak levels. For planners, that can affect referral reliability, network breadth, and geographic coverage.
Supplier concentration and service mix
The strongest concentration signal in the data is that seven of 82 home infusion therapy suppliers provided about 56% of HIT service visits in the prior 12 months (CMS HIT Monitoring Report March 2024). That means a small subset of suppliers carried more than half of all observed volume.
That level of concentration can matter for several reasons:
- Referral patterns may depend on a relatively small number of high-throughput operators.
- Operational disruptions at a few suppliers could affect a disproportionate share of patients.
- Competitive analysis should not treat the market as evenly distributed across all suppliers.
The same report also shows that the HIT benefit covers 37 drugs under the permanent Medicare home infusion therapy benefit (CMS HIT Monitoring Report March 2024). That creates a broad enough therapeutic base to support multiple categories of activity, even though actual service volume is concentrated.
Service mix by visit type
The dataset separates initial from subsequent visits. Initial HIT visits were 896 and represented 3.0% of all HIT visits in the prior 12 months ending June 30, 2023, while subsequent HIT visits were 28,818 and represented 97.0% of all HIT visits over the same period (CMS HIT Monitoring Report March 2024).
That split suggests a service model dominated by ongoing administration rather than first-touch onboarding. In practical terms, outpatient infusion providers are operating a continuation-heavy workflow, where retention and adherence can be just as important as acquisition.
Drug mix by category
The category data is where outpatient infusion becomes more legible from an operational perspective. It shows which drugs drive the most service visits and where the workload is concentrated.
Category volumes
| Category | Visits | Share | Source |
|---|---|---|---|
| Category 1 HIT | 14,777 | n/a | CMS HIT Monitoring Report March 2024 |
| Category 2 HIT | 7,852 | n/a | CMS HIT Monitoring Report March 2024 |
| Category 3 HIT | 7,085 | n/a | CMS HIT Monitoring Report March 2024 |
The Category 1 total is roughly twice the Category 2 and Category 3 totals, so the highest-volume bucket is doing a large share of the work (CMS HIT Monitoring Report March 2024).
Drugs leading each category
For Category 1, milrinone lactate accounted for 13,253 visits and 89.7% of the category (CMS HIT Monitoring Report March 2024). Dobutamine HCl accounted for 683 visits and 4.6%, while treprostinil accounted for 208 visits and 1.4% (CMS HIT Monitoring Report March 2024).
For Category 2, Hizentra accounted for 3,337 visits and 42.5% of the category, Cuvitru accounted for 1,674 visits and 21.3%, and hyaluronidase (Hyqvia) accounted for 1,145 visits and 14.6% (CMS HIT Monitoring Report March 2024).
For Category 3, fluorouracil accounted for 6,734 visits and 95.0% of the category, while blinatumomab accounted for 325 visits and 4.6% (CMS HIT Monitoring Report March 2024).
This is a textbook example of a market where a category may look broad on paper, yet the actual operational workload is driven by one or two products. If you are evaluating staffing, pharmacy preparation, or patient support needs, the dominant drug in each category should matter more than the long tail.
What the mix suggests
- Category 1 is overwhelmingly milrinone-led, so any operational view of this segment should assume that one drug type can define the workflow (CMS HIT Monitoring Report March 2024).
- Category 2 is more distributed, but still clearly led by Hizentra and Cuvitru, with Hyqvia also material (CMS HIT Monitoring Report March 2024).
- Category 3 is highly concentrated in fluorouracil, so its throughput profile will likely track that product closely (CMS HIT Monitoring Report March 2024).
Home IVIG growth and patient profile
The newer home IVIG monitoring data show stronger growth dynamics than the older HIT report. Medicare home IVIG beneficiaries with PIDD claims grew from 36,119 in Q1 2023 to 45,040 in Q2 2025 (CMS Home IVIG Monitoring Report March 2026). That is a sizable increase in the beneficiary base.
The associated utilization metrics also moved higher. Beneficiaries receiving home IVIG drugs grew from 3,329 in Q1 2023 to 3,786 in Q2 2025, and beneficiaries receiving home IVIG visits grew from 1,637 to 2,775 over the same period (CMS Home IVIG Monitoring Report March 2026).
Home IVIG visits themselves increased from 5,007 in Q1 2023 to 8,792 in Q2 2025 (CMS Home IVIG Monitoring Report March 2026). Under the demonstration period, visits increased from 5,007 in Q1 2023 to 5,777 in Q4 2023, then continued rising afterward (CMS Home IVIG Monitoring Report March 2026).
A compact growth view
| Measure | Q1 2023 | Q4 2023 | Q2 2025 | Source |
|---|---|---|---|---|
| Home IVIG visits | 5,007 | 5,777 | 8,792 | CMS Home IVIG Monitoring Report March 2026 |
| Beneficiaries receiving home IVIG drugs | 3,329 | n/a | 3,786 | CMS Home IVIG Monitoring Report March 2026 |
| Beneficiaries receiving home IVIG visits | 1,637 | n/a | 2,775 | CMS Home IVIG Monitoring Report March 2026 |
| Medicare home IVIG beneficiaries with PIDD claims | 36,119 | n/a | 45,040 | CMS Home IVIG Monitoring Report March 2026 |
The growth from Q4 2023 to Q2 2025 is especially useful because it captures post-demonstration momentum. Home IVIG visits increased by 3,015, or 52.2%, from Q4 2023 to Q2 2025 (CMS Home IVIG Monitoring Report March 2026).
Supplier expansion in home IVIG
The supply side expanded alongside the volume. DME suppliers providing home IVIG visits increased from 92 in Q4 2023 to 137 in Q1 2024, a 48.9% increase quarter over quarter, and reached 161 by Q2 2025 (CMS Home IVIG Monitoring Report March 2026).
The number of home IVIG drug suppliers also grew from 182 in Q1 2023 to 222 in Q1 2025, then was 221 in Q2 2025 (CMS Home IVIG Monitoring Report March 2026). That is a very different story from a shrinking or consolidating market. It shows supplier participation broadening even as volumes increased.
Patient profile
The home IVIG recipient mix skews older and female. In Q3 2024 to Q2 2025, there were 2,529 female beneficiaries and 725 male beneficiaries receiving home IVIG visits, and female beneficiaries made up 77.7% of recipients (CMS Home IVIG Monitoring Report March 2026).
Age distribution also matters. Beneficiaries age 65 to under 75 accounted for 1,509 home IVIG visit recipients and 46.4% of the total, while those age 75 to under 85 accounted for 950 and 29.2% (CMS Home IVIG Monitoring Report March 2026). Beneficiaries younger than 65 accounted for 587 recipients and 18.0%, and beneficiaries age 85 and older accounted for 208 and 6.4% (CMS Home IVIG Monitoring Report March 2026).
Eligibility mix shows another practical distinction. Never-dually-eligible beneficiaries accounted for 2,847 home IVIG visit recipients and 87.5% of the total, while any-dual-eligibility beneficiaries accounted for 407 and 12.5% (CMS Home IVIG Monitoring Report March 2026).
Company scale signals in outpatient infusion
The company data help translate these utilization patterns into operating scale.
Option Care Health reported more than 270,000 unique patients and families in 2023 and more than 4,500 clinicians in the same year (Option Care Health 2023 Annual Report). It also operated 177 locations in 43 states, with 93 full-service pharmacies and 84 stand-alone ambulatory infusion suites (Option Care Health 2023 Annual Report). The company expanded to more than 164 centers and over 660 chairs nationwide by 2023 (Option Care Health 2023 Annual Report).
By 2024, Option Care Health reported net revenue of $4.998 billion, up 16.2% year over year, adjusted EBITDA of $443.8 million, up 4.4%, and cash flow from operations of $323.4 million (Option Care Health FY2024 earnings release). It said it would enter 2025 with more than 8,000 team members and more than 5,000 clinicians, and it gave 2025 revenue guidance of $5.3 billion to $5.5 billion (Option Care Health FY2024 earnings release).
InfuSystem provides another angle on outpatient infusion-adjacent infrastructure. It reported full-year 2025 net revenues of $143.4 million, up 6%, with patient services revenue of $86.5 million and device solutions revenue of $64.1 million (InfuSystem FY2025 earnings release). Its third-party payer networks numbered nearly 840 as of December 31, 2025, and its operations spanned seven geographic locations in the U.S. and Canada (InfuSystem FY2025 earnings release; InfuSystem 2025 10-K).
ICU Medical adds a product-manufacturing perspective. It reported infusion systems revenue of $652.4 million in 2024, compared with $629.0 million in 2023 and $617.4 million in 2022, with 2024 revenue growing 3.7% versus 2023 (ICU Medical 2024 Annual Report).
What the company numbers tell you
- Large outpatient infusion providers are operating at national scale with thousands of clinicians and hundreds of locations or service points (Option Care Health 2023 Annual Report; Option Care Health FY2024 earnings release).
- Revenue growth remains material in the largest provider disclosures, which suggests the service model can support expansion when volume and mix improve (Option Care Health FY2024 earnings release).
- Adjacent businesses such as device solutions and payer-network operations remain relevant because outpatient infusion depends on logistics, reimbursement, and care coordination, not just clinical administration (InfuSystem FY2025 earnings release; InfuSystem 2025 10-K).
- Product manufacturers continue to report multi-hundred-million-dollar infusion systems revenue, which indicates that the upstream supply chain is also substantial (ICU Medical 2024 Annual Report).
What these numbers imply for planning
If you are using outpatient infusion statistics to inform operations, market research, or service-line planning, three patterns stand out.
First, demand is real and recurring. The Medicare data show quarterly service volume in the thousands, not hundreds, and the home IVIG series shows a clear upward path through Q2 2025 (CMS HIT Monitoring Report March 2024; CMS Home IVIG Monitoring Report March 2026).
Second, the market is not evenly spread. A small number of suppliers account for a very large share of visits, and a small number of drugs dominate each category (CMS HIT Monitoring Report March 2024). That means the shape of the market depends on concentration, not just total volume.
Third, the largest operators already have the staffing and footprint to handle scale. Option Care Health’s locations, pharmacies, clinicians, and revenue base show what a mature outpatient infusion platform looks like in practice (Option Care Health 2023 Annual Report; Option Care Health FY2024 earnings release).
In other words, outpatient infusion is not a single flat market. It is a layered system where beneficiary growth, supplier participation, drug mix, and operator scale all move together, but not always at the same speed (CMS HIT Monitoring Report March 2024; CMS Home IVIG Monitoring Report March 2026; Option Care Health FY2024 earnings release; InfuSystem FY2025 earnings release; ICU Medical 2024 Annual Report).